RT Journal Article
SR Electronic
T1 Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma: a prospective study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.20.20156398
DO 10.1101/2020.07.20.20156398
A1 Donato, Michele L
A1 Park, Steven
A1 Baker, Melissa
A1 Korngold, Robert
A1 Morawski, Alison
A1 Geng, Xue
A1 Tan, Ming
A1 Ip, Andrew
A1 Goldberg, Stuart
A1 Rowley, Scott
A1 Chow, Kar
A1 Brown, Emily
A1 Zenreich, Joshua
A1 McKiernan, Phyllis
A1 Buttner, Kathryn
A1 Ullrich, Anna
A1 Long, Laura
A1 Feinman, Rena
A1 Rincourt, Andrea
A1 Kemp, Marlo
A1 Vendivil, Mariefel
A1 Suh, Hyung
A1 Balani, Bindu
A1 Cicogna, Cristina
A1 Sebti, Rani
A1 Al-Khan, Abdulla
A1 Sperber, Steven
A1 Desai, Samit
A1 Fanning, Stacey
A1 Arad, Danit
A1 Go, Ronaldo
A1 Tam, Elizabeth
A1 Rose, Keith
A1 Sadikot, Sean
A1 Siegel, David
A1 Gutierrez, Martin
A1 Feldman, Tatyana
A1 Goy, Andre
A1 Pecora, Andrew
A1 Biran, Noa
A1 Leslie, Lori
A1 Gillio, Alfred
A1 Timmapuri, Sarah
A1 Boonstra, Michele
A1 Singer, Sam
A1 Kaur, Sukhdeep
A1 Richards, Ernest
A1 Perlin, David S
YR 2020
UL http://medrxiv.org/content/early/2020/08/04/2020.07.20.20156398.abstract
AB OBJECTIVES To determine the rate of intubation, overall survival, viral clearance, and the development of endogenous antibodies in patients with COVID-19 pneumonia treated with convalescent plasma containing high levels of neutralizing anti-SARS-CoV-2 antibodies. We also aimed to describe the laboratory parameters of the plasma products.DESIGN This was a phase IIa, single institution, prospective study in adults hospitalized with SARS-CoV-2 pneumonia.SETTING Hackensack University Medical Center, a 770-bed research and teaching hospital located in Bergen County NJ, 11 km from New York City. The study was conducted between April 15 and June 18, 2020.PARTICIPANTS 47 hospitalized adult patients were treated: 32 in the non-mechanically ventilated group and 15 in the mechanically ventilated group. All patients had confirmed SARS-CoV-2 pneumonia by radiographic and laboratory evaluation.INTERVENTION Fresh or frozen convalescent plasma from donors with high titers of viral neutralizing antibodies was administered.MAIN OUTCOME MEASURES Incidence of intubation, overall survival, and discharge rate of patients divided in cohorts based on severity of disease. Description of infused plasma characteristics. Evaluation of recipients’ pre-treatment viral immunity, immunity transfer from convalescent plasma administration, and late immunity 30 and 60 days after treatment. Rates of viral clearance by nasopharyngeal PCR at 10 and 30 days. Outcomes of patients with no pre-treatment immunity. Survival comparison with institutional data for each cohort.RESULTS Analysis for the non-mechanically ventilated patients showed an intubation rate of 15.6% (95% CI: 5.3%-32.8%) and a day-30 survival rate of 87.5% (28/32; 95% CI:70.2%-96.4%). The overall survival for a comparative group based on institutional data was 66% (675/1023; p=0.012). The rates of negative nasopharyngeal swab by PR-PCR on day+10 and +30 post treatment were 42.9% (95% CI: 24%-63%) and 78% (95% CI: 56%-93%) respectively. Patients mechanically ventilated had a day-30 mortality of 46.7% (95% CI:21.3%-73.4%); the mortality for a comparative group based on institutional data was 68.5% (217/317; p=0.093). The rates of negative nasopharyngeal swab by PR-PCR at day+10 and +30 was 85.7% (95% CI: 42-100%; n=7) and 100% (95% CI: 63-100%; n=8). Seven patients (15%) had no pre-infusion immunity, and all were found to have anti-SARS-CoV-2 neutralizing titers three days post infusion. All evaluable patients were found to have neutralizing antibodies on day+30 (n=30) and on day+60 (n=12) post treatment. There was no difference in outcomes within the ranges of high antiviral neutralizing titers used, mostly greater than 1:1000. There was also no difference between fresh or frozen plasma. The only adverse event was a mild rash in one patient.CONCLUSION In this study of adult patients hospitalized with SARS-CoV-2 pneumonia, convalescent plasma was safe and conferred effective transfer of immunity while preserving endogenous immune response. Intubation rates, survival rates compared with institutional data, and viral clearance rates, support the continued evaluation of this antiviral modality.STUDY REGISTRATION ClinicalTrials.gov NTC04343755Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNTC04343755Funding StatementFunding This work was supported the COVID Emergency Research Fund #61315, Hackensack University Medical center; by funds provided to the CDI by Activision Publishing Inc, Suez North America, and by NJ Stands Up to COVID.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Hackensack Meridian Health IRB 340 Kingsland Street Nutley, NJ 07110 201-880-3669 ereseach{at}hackensackmeridan.orgAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIn Manuscript